Drug Type Small molecule drug |
Synonyms TRO 40303 |
Mechanism Mitocliondrial permeability transition pore modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H47NO2 |
InChIKeyOBKBVSFXEIFOMS-CEYJMKJVSA-N |
CAS Registry949080-24-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute myocardial infarction | Phase 2 | DK | 01 Oct 2011 | |
Acute myocardial infarction | Phase 2 | FR | 01 Oct 2011 | |
Acute myocardial infarction | Phase 2 | NO | 01 Oct 2011 | |
Acute myocardial infarction | Phase 2 | SE | 01 Oct 2011 | |
Reperfusion Injury | Phase 2 | DK | 01 Oct 2011 | |
Reperfusion Injury | Phase 2 | FR | 01 Oct 2011 | |
Reperfusion Injury | Phase 2 | NO | 01 Oct 2011 | |
Reperfusion Injury | Phase 2 | SE | 01 Oct 2011 |
Phase 2 | 163 | pdsrmexypo(qkfjpgnuiw) = Infarct size, as measured by CK and TnI AUCs at 3 days, was not significantly different between treatment groups. tjrodhfrhl (xkgsxmrfyd ) View more | Negative | 07 Jan 2015 | |||
Placebo |